Most Viewed: Last ONE YEAR
  • Minireview|Open Access

    Updates on hepatorenal syndrome and strategies bridging to liver transplantation

    Chung Yeung Cheung , Kenneth S.H. Chok
    Hepatorenal syndrome is not an uncommon life-threatening complication arising from liver cirrhosis. The diagnostic criteria for this syndrome have been revised throughout the years, with recent revisions aimed at improving earlier diagnosis and treatment. Liver transplantation remains the only definitive treatment for hepatorenal syndrome. Due to the scarcity of liver grafts, many patients die waiting. This review focuses on the different strategies to bridge patients to liver transplantation and to improve the postoperative outcome. Read more
    Hepatoma Res 2017;3:67-72. | doi:10.20517/2394-5079.2016.48
    Published on: 12 Apr 2017  | Viewed:4743  | Downloaded:431
    +HTML| PDF
  • Review|Open Access

    Management of advanced hepatocellular carcinoma: review of current and potential therapies

    Asmaa Gomaa , Imam Waked
    Over the past few years, despite improvement in screening and diagnosis of hepatocellular carcinoma (HCC), advanced stage remains the most common presentation at diagnosis, with limited management options, especially options available to patients in limited resource countries. There is currently no effective systemic chemotherapy, targeted, or immunologic therapy for advanced stage HCC. Sorafenib is the only approved front-line molecular-targeted treatment,with slight survival benefit. Regorafenib has recently been approved as second line therapy for HCC after failure of sorafenib. Ongoing... Read more
    Hepatoma Res 2017;3:112-22. | doi:10.20517/2394-5079.2017.03
    Published on: 15 Jun 2017  | Viewed:4554  | Downloaded:535
    +HTML| PDF
  • Topic: Advances in the diagnosis and treatment of liver fibrosis|Open Access

    Advances in the diagnosis and treatment of liver fibrosis

    Jenny Yeuk-Ki Cheng , Grace Lai-Hung Wong
    Liver fibrosis is the center of diagnosis and management of essentially all chronic liver diseases. While liver biopsy examination still has a role in diagnosis and drug development, it is replaced by non-invasive assessments of liver biopsy in majority of the clinical scenarios. Radiological approaches, namely transient elastography, acoustic radiation force impulse imaging, shear wave elastography, magnetic resonance elastography provide accurate diagnosis of advanced fibrosis and cirrhosis. Serum test formulae based on common laboratory parameters or more specialized parameters including... Read more
    Hepatoma Res 2017;3:156-69. | doi:10.20517/2394-5079.2017.27
    Published on: 8 Aug 2017  | Viewed:3601  | Downloaded:214
    +HTML| PDF
  • Topic: Novel Approaches for HCC|Open Access

    Immunotherapy for hepatocellular carcinoma: the force awakens in HCC?

    Lynn G. Feun , Ying-Ying Li , Medhi Wangpaichitr , Chun-Jing Wu , Niramol Savaraj
    Systemic therapy for hepatocellular carcinoma (HCC) has been disappointing. The only drug approved by Food and Drug Administration recently has been sorafenib. Sorafenib has modest benefits with a low response rate and an improvement in time to progression of only 2-3 months. Multiple randomized trials, which compare the new agent to sorafenib as either first line or second line therapy, have been negative, showing no improved clinical benefit. Recently, in a large phase III randomized trial, regorafenib has shown superiority to placebo as a second line treatment for HCC. However, this drug... Read more
    Hepatoma Res 2017;3:43-51. | doi:10.20517/2394-5079.2016.45
    Published on: 22 Mar 2017  | Viewed:3083  | Downloaded:700
    +HTML| PDF
  • Original Article|Open Access

    In vitro antitumor efficacy of Kochia indica extract on human hepatocellular carcinoma cell line with or without 5-fluorouracil

    Nabil Mohie Abdel-Hamid , Ghada A. Tabl , Yousry E. El-Bolkiny , Walaa O. Zeina
    Aim: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the sixth most common cancer worldwide. The resistance to chemotherapy is a major obstacle in the treatment of HCC, necessitating the discovery of additional agents. There is a growing use of anticancer complementary and alternative medicine worldwide. Therefore, the aim of present study was focused on the confirmation of the suitability and validity of the new markers which would be achieved by demonstrating their significant change and reproducible expression during disease and disease management. Methods:... Read more
    Hepatoma Res 2017;3:149-55. | doi:10.20517/2394-5079.2016.50
    Published on: 21 Jul 2017  | Viewed:2800  | Downloaded:62
    +HTML| PDF
  • Original Article|Open Access

    Late recurrence of hepatocellular carcinoma after liver transplantation

    Julia A. Zhang , Sandi A. Kwee , Linda L. Wong
    Aim: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and liver transplant (LT) prolongs survival. However, 15-20% will experience recurrent HCC, most occurring within 2 years of LT. HCC patients with late recurrences (> 5 years after LT) may have distinctive clinical/biological characteristics. Methods: A retrospective review was conducted of 88 patients who underwent LT for HCC during 1993-2015, analyzing demographics, clinical factors, explant pathology, and outcome. Results: Median follow-up was 6.4 years. HCC recurred in 15 (17.0%) patients with... Read more
    Hepatoma Res 2017;3:58-66. | doi:10.20517/2394-5079.2017.05
    Published on: 10 Apr 2017  | Viewed:1869  | Downloaded:124
    +HTML| PDF
  • Editorial|Open Access

    Liver transplantation in acute-on-chronic liver failure

    Roger Williams
    Hepatoma Res 2017;3:90-4. | doi:10.20517/2394-5079.2017.13
    Published on: 17 May 2017  | Viewed:1739  | Downloaded:118
    +HTML| PDF
  • Original Article|Open Access

    Antioxidant activity and free radical-scavenging of cape gooseberry (Physalis peruviana L.) in hepatocellular carcinoma rats model

    Hanaa A. Hassan , Nermin E. Ghareb , Ghassan F. Azhari
    Aim: Oxidative damage of cellular components by free radicals and other reactive oxygen molecules is believed to be associated with the development of degenerative diseases. The aim of the present study was to evaluate the antioxidant capacity and free radical scavenging activity of cape gooseberry juice (CGJ) in diethylnitrosamine-(DENA) and CCl4 (3 mL/kg b.w.)-induced hepatocellular carcinoma (HCC) rats model. Methods: The rats were divided into 4 groups (6 rats each group). Group 1 (control): the rats of this group did not receive any treatments; group 2 (CGJ): rats were daily... Read more
    Hepatoma Res 2017;3:27-33. | doi:10.20517/2394-5079.2016.33
    Published on: 28 Feb 2017  | Viewed:1715  | Downloaded:140
    +HTML| PDF
  • Viewpoint of Editor-in-Chief|Open Access

    Cancer Evo-Dev, a novel hypothesis derived from studies on hepatitis B virus-induced carcinogenesis

    Guang-Wen Cao
    Non-resolving inflammation, which may be maintained by infection, pollution, and metabolic stimulants and their interactions with immunogenetic predisposition, provides a fertile field for cancer development. This is strongly evident in hepatocellular carcinoma. Here, the framework of a hypothesis called Cancer Evo-Dev is presented, based on the advances in hepatitis B virus-induced hepatocarcinogenesis. Several aspects central to this theory are as follows: (1) immune imbalance caused by the interaction of immunogenetic predispositions and hepatitis B virus infection maintains... Read more
    Hepatoma Res 2017;3:241-59. | doi:10.20517/2394-5079.2017.45
    Published on: 27 Oct 2017  | Viewed:1690  | Downloaded:86
    +HTML| PDF
  • Original Article|Open Access

    Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma

    Hie-Won Hann , Surbhi Jain , Grace Park , Jamin D. Steffen , Wei Song , Ying-Hsiu Su
    Aim: This study aimed to explore the potential of detecting hepatocellular carcinoma (HCC)-associated DNA markers, TP53 249T mutations and aberrant methylation of RASSF1A and GSTP1 genes, for monitoring HCC recurrence. HCC remains a leading cause of death worldwide, with one of the fastest growing incidence rates in the US. While treatment options are available and new ones emerging, there remains a poor prognosis of this disease mostly due to its late diagnosis and high recurrence rate. Although there are no specific guidelines addressing how HCC recurrence should be monitored, recurrence... Read more
    Hepatoma Res 2017;3:105-11. | doi:10.20517/2394-5079.2017.15
    Published on: 6 Jun 2017  | Viewed:1521  | Downloaded:177
    +HTML| PDF
  • Review|Open Access

    Reducing liver cancer risk beginning at birth: experiences of preventing chronic hepatitis B virus infection in China

    Chunfeng Qu , Zhongping Duan , Kun Chen , Huaibin Zou
    In China, the death numbers due to primary liver cancer every year account for more than half of this disease burden worldwide. Hepatocellular carcinoma (HCC) represents the major histological type of primary liver cancer. In the Chinese population, at least 85% HCC cases are due to chronic infection with hepatitis B virus (HBV), most of which were acquired in the perinatal period or in early life. As of January 1992, HBV immunization of newborns was introduced to the national Expended Program of Immunization of China. Prior to this program, the Qidong County in China conducted an hepatitis... Read more
    Hepatoma Res 2017;3:228-40. | doi:10.20517/2394-5079.2017.41
    Published on: 25 Oct 2017  | Viewed:1410  | Downloaded:49
    +HTML| PDF
  • Original Article|Open Access

    Use of gadobenate dimeglumine dynamic MRI for detection of early hepatocellular carcinoma in atypical hepatic focal lesions

    Mohamed F. El-Gazzar , Mohamed Ahmed Samy Kohla , Mahmoud M. El-Sakhawy , Mohamed M. Husseiny , Reda R. H. Yousef , Safinaz H. El-Shorbagy
    Aim: Gadobenate dimeglumine (multihance) is a contrast medium which can be used not only as an extracellular contrast agent for dynamic imaging of the liver, but also as a liver specific agent for the acquisition of hepatobiliary-phase images which are more helpful in evaluation of small atypical hepatic focal lesions equal or less than 3 cm. The authors tried to evaluate multihance dynamic magnetic resonance imaging (MRI) as a new modality in early detection of hepatocellular carcinoma (HCC). Methods: Thirty cirrhotic patients with small hepatic focal lesions (less than 3 cm in diameter),... Read more
    Hepatoma Res 2017;3:123-8. | doi:10.20517/2394-5079.2017.08
    Published on: 26 Jun 2017  | Viewed:1391  | Downloaded:93
    +HTML| PDF
  • Case Report|Open Access

    Hepatocellular carcinoma following direct anti-viral for hepatitis C treatment: a report of an Egyptian case series

    Eman A. Rewisha , Maha M. Elsabaawy , Omar Elshaarawy , Ayat Abdullah , Dalia M. Elsabaawy , Omkolsoum M. Alhaddad
    Egypt had been vexed by the highest load of chronic hepatitis C in the world. It represents a vast market of the new direct-acting anti-viral drugs (DAAs); effectively treating chronic hepatitis C virus (HCV) infection. Eradication of HCV in Egypt has been challenged by the observed increased diagnosis of hepatocellular carcinoma (HCC) in relation to DAAs therapy. This is the first Egyptian report annotating to a series of sixteen chronic HCV infected cases without a diagnosis of HCC before DAAs therapy and unexpected development of HCC during or after completion of DAAs therapy. Read more
    Hepatoma Res 2017;3:178-81. | doi:10.20517/2394-5079.2017.18
    Published on: 11 Aug 2017  | Viewed:1280  | Downloaded:156
    +HTML| PDF
  • Original Article|Open Access

    Comparison of p53 and prohibitin expression in the spectrum of hepatitis, cirrhosis, and hepatocellular carcinoma

    Lívia Maria Della Porta , Fernando Silva Ramalho , Carlos Augusto Oliveira , Deisy Mara Silva , Marlei Josiele Augusto , Leandra Náira Zambelli Ramalho
    Aim: To investigate the correlation of p53 and prohibitin (PHB) expression in the spectrum of hepatitis, cirrhosis, and human hepatocellular carcinoma (HCC). Methods: Hepatic biopsies from patients with HCC (n = 60), cirrhosis (CIR, n = 30), hepatitis C virus (HCV, n = 30), and normal livers (NL, n = 20) were examined for immunohistochemical expression of RelA/p65, tumor necrosis factor receptor-1 (TNFR1), TNF-related apoptosis-inducing ligand (TRAIL), p53, and PHB. The samples were also analysed by nuclear factor kappa B (NFκB) Southwestern histochemistry and a transferase-mediated... Read more
    Hepatoma Res 2017;3:34-42. | doi:10.20517/2394-5079.2016.39
    Published on: 28 Feb 2017  | Viewed:1259  | Downloaded:68
    +HTML| PDF
  • Original Article|Open Access

    MELD score and AST-to-platelet ratio index predict long-term survival in patients with a small hepatocellular carcinoma following non-transplant therapies: a pilot study

    Joy Sarkar , Thomas DeLeon , Linda L. Wong
    Aim: Liver transplantation (LT) is the most effective treatment for long-term survival from hepatocellular carcinoma (HCC); however, insufficient donors limit therapy. The authors sought to identify characteristics that predicted long-term survival after non-transplant therapies in patients with small HCC. Methods: In a database of 1,050 HCC patients, the authors identified those with single HCC ≤ 3.0 cm, who underwent hepatic resection (HR, n = 16), radiofrequency ablation (RFA, n = 55), or LT (n = 23) with 5-year follow-up. Overall survival (OS) and odds-ratios (OR) for survival after... Read more
    Hepatoma Res 2017;3:79-85. | doi:10.20517/2394-5079.2017.06
    Published on: 9 May 2017  | Viewed:1233  | Downloaded:77
    +HTML| PDF
  • Review|Open Access

    Roles of p53 in extrinsic factor-induced liver carcinogenesis

    Tim Link , Tomoo Iwakuma
    Liver cancer remains one of the most common human cancers with a high mortality rate. Therapies for hepatocellular carcinoma (HCC) remain ineffective, due to the heterogeneity of HCC with regard to both the etiology and mutation spectrum, as well as its chemotherapy resistant nature; thus surgical resection and liver transplantation remain the gold standard of patient care. The most common etiologies of HCC are extrinsic factors. Humans have multiple defense mechanisms against extrinsic factor-induced carcinogenesis, of which tumor suppressors play crucial roles in preventing normal cells... Read more
    Hepatoma Res 2017;3:95-104. | doi:10.20517/2394-5079.2017.07
    Published on: 6 Jun 2017  | Viewed:1164  | Downloaded:70
    +HTML| PDF
  • Original Article|Open Access

    Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort

    Scott T. Nishioka , Miles M. Sato , Linda L. Wong , Maarit Tiirikainen , Sandi A. Kwee
    Aim: Increased serum alpha-fetoprotein (AFP) levels are associated with specific molecular sub-classes of hepatocellular carcinoma (HCC), supporting AFP as a predictive or therapeutic biomarker for precision treatment of this disease. Considering recent efforts to validate HCC molecular classification systems across different populations, we applied existing signature-based classification templates to Hawaii cohorts and examined whether associations between HCC molecular sub-class, AFP levels, and clinical features found elsewhere can also be found in Hawaii, a region with a unique... Read more
    Hepatoma Res 2018;4:1. | doi:10.20517/2394-5079.2017.46
    Published on: 12 Jan 2018  | Viewed:1128  | Downloaded:49
    +HTML| PDF
  • Original Article|Open Access

    Laparoscopic liver resection with lymph node dissection for gallbladder tumors suspected to be T1b/T2 carcinoma

    Masashi Isetani , Zenichi Morise , Akihiko Horiguchi
    Aim: The short-term perioperative results of laparoscopic treatment of gallbladder (GB) carcinoma were evaluated to determine whether this technique can be a feasible treatment option. Methods: Ten patients with fundus/body GB tumors (GBTs) underwent laparoscopic liver resection (LLR) and lymph node dissection. Additionally, 124 patients underwent LLR for liver tumors. These 124 LLRs included 79 partial resections (PRs), 11 left lateral sectionectomies (LLSs), 25 anatomical resections (ARs), and 9 small ARs (SARs). The operation time (OT), intraoperative blood loss (BL), and postoperative... Read more
    Hepatoma Res 2017;3:170-7. | doi:10.20517/2394-5079.2017.17
    Published on: 9 Aug 2017  | Viewed:1028  | Downloaded:40
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    Surgical strategy for huge and advanced hepatocellular carcinoma in Hong Kong

    Kenneth S.H. Chok
    In Hong Kong, surgical resection is the core curative treatment for huge and advanced hepatocellular carcinoma (HCC). For tumors measuring 10 cm or above, major hepatectomy is usually required, but a future liver remnant not large enough will preclude the operation. Hypertrophy of future liver remnant is a way to render more patients operable, and measures include portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy. For HCC that has invaded a major vessel, en bloc resection with immediate vessel reconstruction is necessary if thrombectomy... Read more
    Hepatoma Res 2017;3:189-95. | doi:10.20517/2394-5079.2017.33
    Published on: 3 Sep 2017  | Viewed:923  | Downloaded:83
    +HTML| PDF
  • Minireview|Open Access

    Primary hepatic lymphoma: is it a disease entity?

    Fei Xiong , Yong-Song Guan
    It is now widely accepted that lymphoma is a cancer of the lymphatic cells in the immune system and a type of blood cancer that develops when T or B lymphocytes of the white blood cells display uncontrolled proliferation and cellular immortality. Currently, a number of authors have published case reports or case series in which these lesions are defined as primary hepatic lymphoma. This minireview discusses several aspects of the entity of primary hepatic lymphoma, especially the dilemmas in diagnosis. Read more
    Hepatoma Res 2017;3:73-8. | doi:10.20517/2394-5079.2017.02
    Published on: 9 May 2017  | Viewed:902  | Downloaded:63
    +HTML| PDF
  • Original Article|Open Access

    Attenuation of liver stiffness in sorafenib-treated patients with advanced hepatocellular carcinoma

    Chien-Fu Hung , Dong Liu , Tsung-Han Wu , Chao-Wei Lee , Kuang-Tse Pan , Ching-Ting Wang , Hsiu-Ying Chai , Ming-Chin Yu , Yi-Cheng Chen
    Aim: Sorafenib is a multi-tyrosine kinase inhibitor and the standard therapy for advanced hepatocellular carcinoma (HCC). This retrospective study aimed to observe the anti-fibrotic effect of sorafenib in patients with advanced HCC. Methods: Seventeen patients with advanced HCC were recruited. Shear wave velocity (SWV) using acoustic radiation force impulse elastography and non-invasive serum markers for liver fibrosis, such as the aspartate aminotransferase (AST) to alanine aminotransferase ratio (AAR), the AST to platelet ratio index, the fibrosis-4 index and the Lok index, were recorded... Read more
    Hepatoma Res 2017;3:52-7. | doi:10.20517/2394-5079.2016.43
    Published on: 24 Mar 2017  | Viewed:861  | Downloaded:89
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    Outcomes of emergency and interval hepatectomy for ruptured resectable hepatocellular carcinoma: a single tertiary referral centre experience

    Andrew Kai Yip Fung , Charing Ching Ning Chong , Kit Fai Lee , John Wong , Yue Sun Cheung , Anthony Kwong Wai Fong , Paul Bo San Lai
    Aim: The short and long term outcomes of patients who underwent emergency and interval hepatectomy for ruptured and resectable hepatocellular carcinoma (HCC) were analysed. Methods: The data of patients with ruptured HCC presenting between April 2004 and October 2015 were analysed. Emergency hepatectomy was defined as hepatectomy within 48 h of the clinico-radiological diagnosis of HCC rupture. Results: Thirty patients underwent hepatectomy for ruptured HCC. Nine (30%) patients underwent emergency hepatectomy. The median age was 56 and 54 years (P = 0.13) with a similar gender distribution.... Read more
    Hepatoma Res 2017;3:196-204. | doi:10.20517/2394-5079.2017.23
    Published on: 8 Sep 2017  | Viewed:782  | Downloaded:54
    +HTML| PDF
  • Cohort Profile|Open Access

    Qidong hepatitis B virus infection cohort: a 25-year prospective study in high risk area of primary liver cancer

    Tao-Yang Chen , Geng-Sun Qian , Chun-Sun Fan , Yan Sun , Jin-Bing Wang , Pei-Xin Lu , Xue-Feng Xue , Yan Wu , Qi-Nan Zhang , Yan Jin , Yi-Qian Wu , Yu Gan , Jian-Quan Lu , Thomas W. Kensler , John D. Groopman , Hong Tu
    Qidong hepatitis B virus (HBV) infection cohort (QBC) is a prospective community-based study designed to investigate causative factors of primary liver cancer (PLC) in Qidong, China, where both PLC and HBV infection are highly endemic. Residents aged 20-65 years, living in seven townships of Qidong, were surveyed using hepatitis B surface antigen (HBsAg) serum test and invited to participate in QBC from June 1991 to December 1991. A total of 852 and 786 participants were enrolled in HBsAg-positive and HBsAg-negative sub-cohorts in May 1992, respectively. All participants were actively... Read more
    Hepatoma Res 2018;4:4. | doi:10.20517/2394-5079.2017.50
    Published on: 26 Jan 2018  | Viewed:779  | Downloaded:22
    +HTML| PDF
  • Original Article|Open Access

    Hepatocellular carcinoma in the setting of Interferon-free treatment for chronic HCV hepatitis - experience of a single center

    Elena Laura Iliescu , Adriana Mercan-Stanciu , Letitia Toma , Elena Simona Ioanitescu , Radu Dumitru , Daniel Rusie
    Aim: This study aims to analyze the particularities of hepatitis C induced hepatocellular carcinoma (HCC), developed during or after treatment with direct-acting antivirals. Methods: We conducted an observational prospective study on 278 patients, who underwent treatment for hepatitis C related liver cirrhosis and respectively for F3 chronic hepatitis C. Liver status was assessed using biological parameters and imagistic evaluation (ultrasonography, computed tomography scan, magnetic resonance imaging). Results: The follow-up time was 14 months. Before therapy, 69.3% of the cirrhotic... Read more
    Hepatoma Res 2018;4:3. | doi:10.20517/2394-5079.2017.48
    Published on: 18 Jan 2018  | Viewed:733  | Downloaded:15
    +HTML| PDF
  • Original Article|Open Access

    Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy

    Glenn W. Stambo , Deborah Cragan
    Aim: The purpose of this study was to evaluate and compare how hepatocellular carcinoma (HCC) and colorectal metastases respond to LC Bead chemoembolization using doxorubicin and irinotecan. Methods: The authors report their experience with doxorubicin and irinotecan eluting beads to treat 13 patients with primary HCC and 25 patients with colorectal metastases over a 1-year period at a single community based oncology practice. Within the colorectal cancer group they compared irinotecan eluting beads to doxorubicin eluting beads. Results: Nine of the 11 (81.8%) doxorubicin treated HCC... Read more
    Hepatoma Res 2017;3:141-8. | doi:10.20517/2394-5079.2017.12
    Published on: 12 Jul 2017  | Viewed:713  | Downloaded:75
    +HTML| PDF
  • Review|Open Access

    Role of early growth response 1 in liver metabolism and liver cancer

    Nancy Magee , Yuxia Zhang
    The liver is an essential organ for nutrient and drug metabolism - possessing the remarkable ability to sense environmental and metabolic stimuli and provide an optimally adaptive response. Early growth response 1 (Egr1), an immediate early transcriptional factor which acts as a coordinator of the complex response to stress, is induced during liver injury and controls the expression of a wide range of genes involved in metabolism, cell proliferation, and inflammation. In support of an important role of Egr1 in liver injury and repair, deficiency of Egr1 delays liver regeneration process.... Read more
    Hepatoma Res 2017;3:268-77. | doi:10.20517/2394-5079.2017.36
    Published on: 20 Nov 2017  | Viewed:707  | Downloaded:41
    +HTML| PDF
  • Review|Open Access

    Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma

    Man Zhu , Yan-Min Zhang
    Hepatocellular carcinoma (HCC) remains a challenging disease with a high recurrence rate after surgery and there is an imminent need to identify new treatments. Currently, adjuvant therapy like chemotherapeutics arises to counteract the malignant trait escaping from apoptosis of tumors induced by overexpressed anti-apoptotic factors in HCC. Myeloid cell leukaemia-1 (Mcl-1) as an anti-apoptotic member of Bcl-2 is highly expressed in diverse human cancers, which contributes to cancer cell survival and the resistance to diverse chemotherapeutic agents. It is confirmed that Mcl-1 protein... Read more
    Hepatoma Res 2017;3:129-40. | doi:10.20517/2394-5079.2017.14
    Published on: 6 Jul 2017  | Viewed:665  | Downloaded:71
    +HTML| PDF
  • Original Article|Open Access

    Neoplastic macrovascular invasion represents an independent risk factor for dismal survival in sorafenib treatment for hepatocellular carcinoma

    Michele Lecchini , Andrea Olivani , Elisabetta Biasini , Raffaele Dalla Valle , Carlo Ferrari , Gabriele Missale , Claudia Schianchi
    Aim: Sorafenib efficacy and safety in advanced hepatocellular carcinoma (HCC) have been demonstrated in two randomized international clinical trials and in clinical practice studies. Because of poor survival advantage, to identify clinical and biological parameters remains an unmet clinical need. Methods: Eighty-four patients treated with sorafenib were evaluated for response to therapy and prognostic factors possibly associated with survival. Results: Median overall survival was 8.5 months. Median duration of therapy was 2.5 months with a median daily dose of 800 mg (IQR 600-800). Dose was... Read more
    Hepatoma Res 2017;3:260-7. | doi:10.20517/2394-5079.2017.44
    Published on: 16 Nov 2017  | Viewed:638  | Downloaded:38
    +HTML| PDF
  • Case Report|Open Access

    First case report of inflammatory myofibroblastic tumor of peritoneal cavity in a living donor liver transplantation recipient

    Naganathan Selvakumar , Parul Saboti , Sumaid Kaul , Subash Gupta
    Post-transplantation malignancies are well known complications after liver transplantation. Certain malignancies are more common in pediatric recipients than adults. Inflammatory myofibroblastic tumors (IMTs) are reactive neoplasms with miniscule malignant potential. IMTs are more common after hematopoietic stem cell transplantation. However, there is 1 case reported in the literature after deceased donor liver transplantation. The authors describe a case of IMT after living donor liver transplantation. The patient was a 1-year-old girl who underwent living donor liver transplantation... Read more
    Hepatoma Res 2017;3:86-9. | doi:10.20517/2394-5079.2017.01
    Published on: 17 May 2017  | Viewed:626  | Downloaded:51
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    Robotic hepatectomy for hepatocellular carcinoma: a clinical review

    Eric C.H. Lai , Daniel T.M. Chung , Oliver C.Y. Chan , Chung Ngai Tang
    The robotic surgical system was developed to overcome the disadvantages of conventional laparoscopic surgery. The use of robots in liver surgery was not well evaluated. This article aimed at reviewing robotic partial hepatectomy to conventional laparoscopic or open partial hepatectomy in terms of perioperative, oncologic, and healthcare costs for hepatocellular carcinoma (HCC). Studies were identified by searching MEDLINE and PubMed databases for articles from January 2004 to June 2017 using the keywords "laparoscopic hepatectomy", "robotic surgery", "robotic hepatectomy", and... Read more
    Hepatoma Res 2017;3:278-83. | doi:10.20517/2394-5079.2017.37
    Published on: 27 Nov 2017  | Viewed:583  | Downloaded:9
    +HTML| PDF
  • Original Article|Open Access

    Efficacy and HCC development after DAA therapy for patients with chronic hepatitis C: a single center retrospective cohort study

    Akitoshi Douhara , Hiroyuki Ogawa , Satoshi Nakatani , Takahiro Ozutsumi , Erika Shioyama , Masaaki Yoshikawa , Shigehiko Ueda
    Aim: The development of hepatocellular carcinoma (HCC) is reduced after interferon based treatment in patients with chronic hepatitis C (CHC). A new therapy using direct-acting antiviral agents (DAA) has been widely applied since 2014 for CHC. The purpose of this study is to investigate the efficacy, safety and development of HCC after DAA treatment. Methods: The authors enrolled 33 consecutive patients who were treated with DAA for CHC at the hospital between January 2015 and March 2016. The laboratory data were collected at the start and 24 weeks after DAA therapy. Results: The authors... Read more
    Hepatoma Res 2017;3:215-20. | doi:10.20517/2394-5079.2017.32
    Published on: 17 Oct 2017  | Viewed:568  | Downloaded:39
    +HTML| PDF
  • Original Article|Open Access

    Transcatheter arterial chemoembolization in recurrent unresectable hepatocellular carcinoma after orthotopic liver transplantation

    Hasmukh J. Prajapati , Pavan Kavali , Hyun S. Kim
    Aim: To investigate the survivals and efficacy of the doxorubicin drug eluting beads transcatheter arterial chemoembolization (TACE) in patients with recurrent hepatocellular carcinoma (HCC) status post orthotopic liver transplantation. Methods: Consecutive patients with HCC who underwent orthotopic liver transplantation from 2005 to 2012 were reviewed. Patients who developed recurrent HCC after orthotopic liver transplantation and received doxorubicin drug eluting beads TACE therapy were identified and included in the study. Survivals were calculated from the time of 1st doxorubicin drug... Read more
    Hepatoma Res 2017;3:182-8. | doi:10.20517/2394-5079.2017.25
    Published on: 17 Aug 2017  | Viewed:502  | Downloaded:44
    +HTML| PDF
  • Original Article|Open Access

    Comparison of outcomes between laparoscopic vs. open liver resection for intermediate stage hepatocellular carcinoma

    Avril David , YoungRok Choi , Ho-Seong Han , Yoo-Seok Yoon , Jai Young Cho
    Aim: The Barcelona Clinic Liver Score (BCLC) currently limits hepatic resection only for small, solitary tumors measuring 2-3 cm with no signs of portal hypertension (PHT) or macrovascular invasion. The aim of this study was to show the benefit of surgical resection, and to compare the peri-operative and long-term outcomes between laparoscopic liver resection (LLR) and open liver resection (OLR) for hepatocellular carcinoma (HCC) classified as intermediate stage (B) under BCLC. Methods: From 2004 to 2013, 49 patients staged as intermediate (BCLC B) and who underwent hepatic resection was... Read more
    This article belongs to the Special Issue Management of Huge and Advanced Hepatocellular Carcinoma
    Hepatoma Res 2018;4:2. | doi:10.20517/2394-5079.2017.51
    Published on: 18 Jan 2018  | Viewed:442  | Downloaded:29
    +HTML| PDF
  • Review|Open Access

    Interventional radiology for post-transplant anastomotic complications

    Toshiya Shibata
    The effectiveness of percutaneous interventional radiology for anastomotic stricture in hepatic vein, portal vein, and biliary tract after living donor liver transplantation (LDLT) is described. As a number of patients with LDLT are infants < 10-year-old in the study, the first treatment option was balloon dilatation, not primary stenting. However, stent placement was performed in patients with recurrent, repeated stenosis. Read more
    Hepatoma Res 2017;3:221-7. | doi:10.20517/2394-5079.2017.34
    Published on: 25 Oct 2017  | Viewed:433  | Downloaded:9
    +HTML| PDF
  • Original Article|Open Access

    Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

    Estefania Berge , Ana Arencibia , Elena Otón , Luis Cejas , Silvia Acosta , Francisco Pérez
    Aim: The aim was to assess the clinical impact of direct-acting antiviral treatment in patients with compensated hepatitis C virus-related cirrhosis after one year of follow-up. Methods: An observational retrospective study was conducted on 129 consecutive patients with compensated cirrhosis treated in 2015, analyzing the evolution of liver function and the development of hepatocellular carcinoma and clinical decompensations. Results: The median follow-up time was 16 months. Most patients were males (73%), the mean age was 58.1 years and the most frequent genotype was 1b (52.2%). All... Read more
    Hepatoma Res 2017;3:209-14. | doi:10.20517/2394-5079.2017.28
    Published on: 27 Sep 2017  | Viewed:425  | Downloaded:34
    +HTML| PDF
  • Case Report|Open Access

    Total regression of hepatocellular carcinoma bone metastases, after liver transplantation, with sorafenib-everolimus

    Dimitrios Giakoustidis , Athanasios Apostolos Gargavanis , Nikolaos Salveridis , Evangelos Cholongitas , Emmanouil Sinakos , Konstantinos Papapolychroniadis , Vasileios Papanikolaou
    Hepatocellular carcinoma (HCC) represents the 5th commonest malignancy worldwide. Liver transplantation consist a radical and most efficient treatment for HCC. Tumor recurrence or metastases after liver transplantation is not uncommon. Hereby is presented a case of a patient transplanted for alcoholic liver disease and HCC and presented with bone metastases a few months later. Treatment with sorafenib and everolimus showed full regression of the metastases. In conclusion, the point of this report is to advertise a single case of total regression of bone lesions due to HCC recurrence, with... Read more
    Hepatoma Res 2017;3:205-8. | doi:10.20517/2394-5079.2017.29
    Published on: 20 Sep 2017  | Viewed:423  | Downloaded:28
    +HTML| PDF
  • Topic: Management of Huge and Advanced Hepatocellular Carcinoma|Open Access

    The role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma

    James Fung , Kenneth S.H. Chok
    Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) in places where chronic hepatitis B infection is endemic. Oral nucleos(t)ide analog (NA) therapy can reduce the risk of HCC, but cannot completely prevent its development. For HBV-related HCCs, viral inhibition by NAs can preserve or improve liver function, thereby increasing the chance of therapeutic intervention. After surgical resection, NAs can prevent reactivation of HBV, and also reduce the chance of de novo development of HCC in the remnant liver. For those who undergo liver transplantation, NAs are... Read more
    Hepatoma Res 2017;3:284-93. | doi:10.20517/2394-5079.2017.38
    Published on: 27 Nov 2017  | Viewed:419  | Downloaded:25
    +HTML| PDF
  • Original Article|Open Access

    Association of serum levels of transforming growth factor β1 with disease severity in patients with hepatocellular carcinoma

    Mohamed Ahmed Samy Kohla , Ahmed Attia , Nehad Darwesh , Manar Obada , Hossam Taha , Marwa F. Youssef
    Aim: Transforming growth factor (TGF) is overexpressed by tumor cells like other proteins and growth factors. TGF-β1 is then activated in the extracellular compartment but is unable to control cell proliferation because of the absence or low level of TGF-β1 receptors on the plasma membrane of malignant hepatocytes. This potential mechanism might interrupt the autocrine regulation loop of TGF-β1 and its blocking effect on cell proliferation. TGF-β1 is a multifunctional cytokine involved in the regulation of growth and differentiation of both normal and transformed cells. This study aimed to... Read more
    Hepatoma Res 2017;3:294-301. | doi:10.20517/2394-5079.2017.40
    Published on: 12 Dec 2017  | Viewed:381  | Downloaded:29
    +HTML| PDF
  • Review|Open Access

    Treatment of high-burden hepatocellular carcinoma: an oncologist perspective

    Landon L. Chan , Stephen L. Chan
    Hepatocellular carcinoma (HCC) is recognized as a major global healthcare burden. Although there have been tremendous improvements in cancer screening and treatment, HCC mortality rate remains high. Many patients with HCC present late to medical attention and thus are not candidates for curative treatment. They typically have high tumor burden at presentation showing heterogeneity in anatomical factors and biochemical profile. Despite the relatively poor prognosis for these patients, significant improvements can still be made in survival if the optimal treatment modality is chosen.... Read more
    Hepatoma Res 2018;4:5. | doi:10.20517/2394-5079.2017.49
    Published on: 7 Feb 2018  | Viewed:321  | Downloaded:13
    +HTML| PDF
  • Topic: Novel Approaches for HCC|Open Access

    The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

    Walid S. Ayoub , Francis Dailey , Paul Martin , Patricia D. Jones
    Worldwide, hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality. In men, it is the fifth most common cancer and seventh most common in women; HCC is the second highest cause of cancer-related death worldwide. It is less prevalent in the USA and Northern Europe and more prevalent in Eastern and South-Eastern Asia. Over 700,000 cases are diagnosed each year - half of which occur in China - and result in roughly the same number of deaths per year. HCC significantly impairs quality of life and is associated with great costs to society. It is estimated that half of... Read more
    Hepatoma Res 2017;3:302-8. | doi:10.20517/2394-5079.2016.44
    Published on: 20 Dec 2017  | Viewed:316  | Downloaded:22
    +HTML| PDF
  • Review|Open Access

    Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum

    Federica Buonfiglioli , Stefano Brillanti
    Direct antiviral therapy has dramatically changed our possibility to eradicate hepatitis C virus (HCV) infection in all stages of chronic liver disease, with sustained virological response rates well above 90%. HCV eradication should lead to a better prognosis even after cirrhosis has established, including a reduced risk of developing hepatocellular carcinoma (HCC). Unfortunately, during the last two years different reports have raised the concern about a possible increased risk of developing HCC in cirrhotic patients treated with direct antivirals. In this review, we have evaluated the... Read more
    Hepatoma Res 2018;4:6. | doi:10.20517/2394-5079.2017.42
    Published on: 10 Feb 2018  | Viewed:184  | Downloaded:24
    +HTML| PDF
Hepatoma Research Print ISSN: 2394-5079; Online ISSN: 2454-2520
Quick Links
  • OAE Publishing Inc. (OAE) is an online open-access publisher specializing in the publication of biomedical peer-reviewed journals...

  • Contact us
  • Leave feedback
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.